Payment Reform Models

The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”

Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.

NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for symptomatic brain progression.

KFF finds 4.3 million Medicare beneficiaries will lose their MA or stand-alone Part D plans at the end of 2026, as PDP options keep shrinking.

FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.

Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.

CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.

At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.